Trade Names:Tenoretic-50- Tablets 50 mg atenolol/25 mg chlorthalidone
Trade Names:Tenoretic-100- Tablets 100 mg atenolol/25 mg chlorthalidoneApo-Atenidone (Canada)Tenoretic (Canada)
Atenolol is a beta-adrenergic blocking agent that slows heart rate, reduces cardiac output and lowers BP. Chlorthalidone is a diuretic agent that reduces body water by increasing urine output.
Treatment of hypertension.
Hypersensitivity to sulfonamide-derived drugs, sinus bradycardia, heart block greater than first degree, cardiogenic shock, overt cardiac failure, anuria. Not for initial therapy of hypertension.
PO 50 mg atenolol/25 mg chlorthalidone or 100 mg atenolol/25 mg chlorthalidone once daily.
Store at room temperature in tightly closed, light-resistant container.
Beta-blockers may exacerbate rebound hypertension associated with clonidine withdrawal. Atenolol/chlorthalidone should be tapered and withdrawn several days before gradual withdrawal of clonidine.Digitalis glycosides
Diuretic-induced hypokalemia may potentiate digitalis toxicity.Lithium
May increase therapeutic and toxic effects of lithium; avoid concomitant use.Nondepolarizing muscle relaxants
May increase effects of these agents.Norepinephrine
May decrease arterial responsiveness to norepinephrine.Other antihypertensive agents
May increase antihypertensive effects.Sulfonylureas
May decrease hypoglycemic effects.
May increase serum protein-bound iodine levels without signs of thyroid disturbances.
Bradycardia; orthostatic hypotension; cold extremities; leg pain; CHF; slow atrioventricular (AV) conduction; intensification of AV block.
Fatigue; dizziness; vertigo; light-headedness; lethargy; drowsiness; depression; dreaming.
Peyronie disease; impotence; diminished libido.
Elevated liver enzymes; jaundice; pancreatitis.
Hyperuricemia; hyponatremia; hypochloremic alkalosis; hypokalemia.
Bronchospasm; wheezing; dyspnea.
Development of lupus syndrome with antinuclear antibodies.
Withhold medication and notify health care provider if the following symptoms occur: hypotension; bradycardia or dyspnea; difficulty breathing on exertion or lying down; night cough; edema of hands and feet.
Category D .
Atenolol is excreted in breast milk and may produce clinically significant effects in infants.
Safety and efficacy not established.
Dose may need to be reduced.
Use with caution in patients with renal disease; dose may need to be reduced.
Use with caution in patients with hepatic disease; dose may need to be reduced.
Deaths have occurred with anaphylactic reactions to beta-blockers; aggressive therapy may be required.
Use with caution in patients with history of heart failure.
May mask symptoms of hypoglycemia (eg, tachycardia, BP changes). May potentiate insulin-induced hypoglycemia.
Fixed-dose combinations of drugs are not intended for initial therapy of hypertension but are used for convenience once patient has been stabilized.
In general, do not give beta-blockers to patients with bronchospastic diseases.
May precipitate or aggravate symptoms of arterial insufficiency.
May mask clinical signs (eg, tachycardia) of developing or continuing hyperthyroidism. Abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm.
Copyright © 2009 Wolters Kluwer Health.